Previous 10 | Next 10 |
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product Alvotech (NASDAQ: ALVO), a global biotech compa...
2024-05-21 08:39:19 ET More on Alvotech, Dr. Reddy's, etc. Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech (ALVO) Q4 2023 Earnings Call Transcript Teva, Alvotech...
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product HYDERABAD, India and REYKJAVIK, Iceland, May ...
CXApp Inc. (CXAI) is expected to report for quarter end 2024-03-31 Purple Biotech Ltd. (PPBT) is expected to report $-0.15 for Q1 2024 AutoZone Inc. (AZO) is expected to report $35.72 for Q3 2024 Turkcell Iletisim Hizmetleri AS (TKC) is expected to report for Q1 2024 Orkla ASA ADR...
2024-05-21 06:51:13 ET More on AbbVie, Alvotech, etc. AbbVie, Inc. (ABBV) Bank of America Health Care Conference Call Transcript Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript) Teva Pharmaceutical: 6 Takeaways Fr...
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira ® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvote...
REYKJAVIK, Iceland, May 13, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2024, ...
REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be participating in the upcoming BofA Securities ...
2024-04-30 11:56:42 ET More on Alvotech Alvotech: Consider Buying As Positive Q1 Earnings Release Likely Alvotech (ALVO) Q4 2023 Earnings Call Transcript Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S. FDA approves Alvotech bios...
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration in...
News, Short Squeeze, Breakout and More Instantly...
Launch of European-made Uzpruvo in Europe comes immediately upon expiry of exclusivity rights for the molecule used to treat certain conditions in gastroenterology 1 , dermatology and rheumatology Creates competition at earliest opportunity, enabling straightforward switching to broaden p...
REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facil...
2024-07-09 15:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...